A Phase 3 interventional study of Methotrexate and ocrelizumab in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-27.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 8th largest by enrollment of the 141 interventional ones that give a count, is one of 13 that started in 2006, is one of 85 in phase 3, and was the 25th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Brazil, Poland
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Belgium and 9 more countries
Ages 18+
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
219 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 22 · Phase 3 85 · Phase 4 28
First in 2001; this study’s year is marked. 13 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,015 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 132 across the 141 interventional studies, 182 across the 78 observational. Of the 214 that completed or were terminated, 139 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add it to your calendar (.ics) → With an account.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg - 25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment is 1-2 years. Target sample size is 1000.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
Drug: Methotrexate · Drug: Placebo
Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
Drug: Methotrexate · Drug: ocrelizumab
Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
Drug: Methotrexate · Drug: ocrelizumab
Methotrexate tablet was administered orally at a dose 7.5-25 mg
Ocrelizumab was administered via IV infusion at a dose specified in arm description
Matching placebo to ocrelizumab was administered via IV infusion
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24
ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
Time frame: Week 24
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48
ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
Time frame: Week 48
Percentage of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. Pre-existing conditions which worsened during the study were also reported as AEs.
Time frame: From baseline up to 8.5 years
Percentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 48
ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
Time frame: Week 48
Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 < 2.6) at Weeks 24 and 48
The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.
Time frame: Weeks 24 and 48
Change From Baseline in DAS28 at Weeks 24 and 48
The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.
Time frame: Weeks 24 and 48
European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders) at Weeks 24 and 48
DAS 28 score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and ESR. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline \< -1.2. EULAR Moderate response: DAS28 \>3.2 to ≤ 5.1 or a change from Baseline \< -0.6 to ≥ -1.2.
Time frame: Weeks 24 and 48
Percentage of Participants Achieving an ACR50 Response at Weeks 24 and 48
ACR50 is defined as 50 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
Time frame: Weeks 24 and 48
Percentage of Participants Achieving an ACR70 Response at Weeks 24 and 48
ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
Time frame: Weeks 24 and 48
Percent Change From Baseline in Swollen Joint Count (SJC) at Weeks 24 and 48
66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.
Time frame: Baseline, Week 24, 48
Change From Baseline in Tender Joint Count (TJC) at Weeks 24 and 48
68 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.
Time frame: Baseline, Weeks 24, 48
Change From Baseline in Patient's Pain Visual Analogue Scale (VAS) at Weeks 24 and 48
The patient assessed their pain on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change indicated improvement.
Time frame: Baseline, Week 24, 48
Change From Baseline in Physician's Global VAS at Weeks 24 and 48
The physician's global assessment of disease activity is assessed on a 0 to 100 millimetres (mm) horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).
Time frame: Baseline, Week 24, 48
Change From Baseline in Patient's Global VAS at Weeks 24 and 48
The patient's global assessment of disease activity is assessed on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 24, 48
Change From Baseline in C-Reactive Protein (CRP) at Weeks 24 and 48
The serum concentration of C-Reactive Protein (CRP) is measured in milligrams per deciliter (mg/dL). A reduction in the level is considered an improvement.
Time frame: Baseline, Week 24, 48
Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Weeks 24 and 48
HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.
Time frame: Baseline, Week 24, 48
Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) at Weeks 24 and 48
HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.
Time frame: Baseline, Week 24, 48
Change From Baseline in the Modified Total Sharp Score (mTSS) at Weeks 24 and 48
mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Baseline, Week 24, 48
Change From Baseline in Modified Erosion Score at Weeks 24 and 48
The erosion score is a summary of erosion severity in 32 joints of the hands (16 joints per hand) and 12 joints in the feet (6 joints per foot). Each joint is scored, according to the surface area involved, from 0 to 5, with 5 indicating extensive loss of bone from more than one-half of the articulating bone (0 indicates no erosion). Because each side of a foot joint is graded separately on this scale, the maximum erosion score for a foot joint is 10. The maximal erosion score is 280.
Time frame: Baseline, Week 24, 48
Change From Baseline in Modified Joint Space Narrowing Score at Weeks 24 and 48
The joint space narrowing score summarizes the severity of joint space narrowing in 30 joints of the hands and 12 joints of the feet. Assessment of joint space narrowing for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no/normal joint space narrowing and 4 indicating complete loss of joint space, bony ankylosis, or luxation. The maximum joint space narrowing score is 168.
Time frame: Baseline, Week 24, 48
Percentage of Participants Without Radiographic Progression Defined as Change in mTSS ≤ 0 at Weeks 24 and 48
Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage.
Time frame: Weeks 24, 48
Percentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 48
mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Baseline, Week 48
Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score at Weeks 24 and
HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.
Time frame: Week 24, 48
Change From Baseline in Short Form Health Survey (SF-36) Subscale and Summary Scores at Weeks 24 and 48
The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical and Mental Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.
Time frame: Baseline, Week 24, 48
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Fatigue Assessment at Weeks 24 and 48
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.
Time frame: Baseline, Week 24, 48
Change From Baseline in Pain Quality and Impact of Pain on Daily Function Measured by the Brief Pain Inventory (BPI) Short Form at Weeks 24 and 48
The modified BPI (short-form) is a short questionnaire to assess the severity of pain and the impact of pain on daily functions. The first two questions relate to average and current pain respectively and are assessed on a scale from 0 to 10, where 0 represents no pain, and 10 represents pain as bad as one can imagine. The degree to which pain has interfered with 7 different aspects is also rated on a scale from 0 to 10, where 0 represents that pain does not interfere and 10 that pain completely interferes.
Time frame: Baseline, Week 24, 48
| Milestone | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Started | 324 | 344 | 347 |
| Completed | 0 | 0 | 0 |
| Not completed | 324 | 344 | 347 |
| Withdrew: Death | 3 | 1 | 4 |
| Withdrew: Protocol violation | 6 | 2 | 5 |
| Withdrew: Study terminated by sponsor | 260 | 288 | 282 |
| Withdrew: Withdrawal by subject | 17 | 24 | 26 |
| Withdrew: Lack of efficacy | 12 | 1 | 6 |
| Withdrew: Non-compliance with study drug | 5 | 6 | 3 |
| Withdrew: Adverse event | 10 | 12 | 16 |
| Withdrew: Lost to follow-up | 11 | 10 | 5 |
ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
| Percentage of participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 | 35.7 (30.5 to 41.0) | 56.9 (51.6 to 62.1) | 54.5 (49.2 to 59.8) |
ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
| Percentage of participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48 | 27.6 (22.7 to 32.5) | 58.3 (53.1 to 63.5) | 62.1 (57.0 to 67.2) |
An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. Pre-existing conditions which worsened during the study were also reported as AEs.
| Percentage of participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 79.4 | 82.2 | 83.7 |
ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
| Percentage of participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Percentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 48 | 0.9 (0.0 to 2.0) | 6.1 (3.6 to 8.7) | 7.3 (4.5 to 10.0) |
The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.
| Percentage of participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Week 24 | 5.3 (2.9 to 7.8) | 7.9 (5.0 to 10.7) | 10.8 (7.5 to 14.1) |
| Week 48 | 5.3 (2.9 to 7.8) | 16.0 (12.2 to 19.9) | 17.5 (13.5 to 21.5) |
The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.
| Units on a Scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Baseline | 6.42 ± 1.103 | 6.40 ± 1.143 | 6.40 ± 1.077 |
| Change at Week | -1.33 ± 1.329 | -2.00 ± 1.248 | -2.02 ± 1.310 |
| Change at Week 48 | -1.38 ± 1.290 | -2.42 ± 1.504 | -2.68 ± 1.475 |
DAS 28 score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and ESR. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline \< -1.2. EULAR Moderate response: DAS28 \>3.2 to ≤ 5.1 or a change from Baseline \< -0.6 to ≥ -1.2.
| Percentage of participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Week 24 | 41.6 | 68.8 | 70.0 |
| Week 48 | 35.3 | 65.9 | 72.0 |
ACR50 is defined as 50 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
| Percentage of participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Week 24 | 16.3 (12.2 to 20.4) | 31.8 (26.9 to 36.7) | 31.2 (26.3 to 36.1) |
| Week 48 | 12.9 (9.2 to 16.5) | 39.9 (34.8 to 45.1) | 36.7 (31.6 to 41.8) |
ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).
| Percentage of participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Week 24 | 5.6 (3.1 to 8.2) | 14.3 (10.6 to 18.0) | 12.2 (8.8 to 15.7) |
| Week 48 | 6.6 (3.8 to 9.3) | 20.7 (16.4 to 25.0) | 22.4 (18.0 to 26.9) |
66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.
| Percentage of Change | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Change at Week 24 | -38.20 ± 66.127 | -51.82 ± 80.805 | -54.76 ± 39.896 |
| Change at Week 48 | -39.39 ± 59.184 | -61.36 ± 44.414 | -64.22 ± 65.234 |
68 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.
| Tendor joins | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Change at Week 24 | -36.97 ± 58.675 | -55.11 ± 37.962 | -51.07 ± 49.700 |
| Change at Week 48 | -35.91 ± 64.358 | -61.51 ± 37.229 | -59.55 ± 48.474 |
The patient assessed their pain on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change indicated improvement.
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Change at Week 24 | -9.10 ± 109.646 | -32.02 ± 88.637 | -27.73 ± 139.732 |
| Change at Week 48 | -2.28 ± 148.933 | -38.86 ± 104.267 | -32.47 ± 197.692 |
The physician's global assessment of disease activity is assessed on a 0 to 100 millimetres (mm) horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Change at Week 24 | -40.23 ± 39.655 | -51.44 ± 34.669 | -53.02 ± 34.479 |
| Change at Week 48 | -41.60 ± 43.285 | -61.29 ± 31.543 | -62.10 ± 30.866 |
The patient's global assessment of disease activity is assessed on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Change at Week 24 | -20.73 ± 74.480 | -37.96 ± 83.908 | -36.99 ± 79.130 |
| Change at Week 48 | -17.13 ± 100.706 | -42.02 ± 103.526 | -55.26 ± 37.873 |
The serum concentration of C-Reactive Protein (CRP) is measured in milligrams per deciliter (mg/dL). A reduction in the level is considered an improvement.
| Milligrams per deciliter (mg/dL) | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Change at Week 24 | 11.64 ± 116.697 | -30.41 ± 109.193 | -23.07 ± 109.193 |
| Change at Week 48 | 22.01 ± 190.346 | -40.89 ± 90.139 | 15.14 ± 820.007 |
HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.
| Percentage Change from Baseline | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Change at Week 24 | -20.11 ± 48.921 | -30.12 ± 86.217 | -40.83 ± 38.243 |
| Change at Week 48 | -22.67 ± 57.893 | -35.47 ± 78.670 | -45.63 ± 39.241 |
HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.
| Percentage Change from Baseline | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Change at Week 24 | -2.51 ± 66.453 | -20.10 ± 90.059 | -29.98 ± 57.195 |
| Change at Week 48 | -2.72 ± 57.893 | -27.24 ± 147.973 | -41.19 ± 55.485 |
mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Baseline | 33.58 ± 51.106 | 31.45 ± 51.323 | 31.99 ± 49.602 |
| Change at Week 24 | 1.04 ± 2.842 | 0.34 ± 2.424 | -0.03 ± 2.534 |
| Change at Week 48 | 1.74 ± 5.293 | 0.26 ± 2.791 | -0.03 ± 2.911 |
The erosion score is a summary of erosion severity in 32 joints of the hands (16 joints per hand) and 12 joints in the feet (6 joints per foot). Each joint is scored, according to the surface area involved, from 0 to 5, with 5 indicating extensive loss of bone from more than one-half of the articulating bone (0 indicates no erosion). Because each side of a foot joint is graded separately on this scale, the maximum erosion score for a foot joint is 10. The maximal erosion score is 280.
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Baseline | 17.10 ± 27.256 | 16.22 ± 27.875 | 16.24 ± 26.103 |
| Change at Week 24 | 0.61 ± 1.778 | 0.18 ± 1.487 | 0.04 ± 1.511 |
| Change at week 48 | 1.06 ± 3.238 | 0.08 ± 1.690 | -0.08 ± 1.588 |
The joint space narrowing score summarizes the severity of joint space narrowing in 30 joints of the hands and 12 joints of the feet. Assessment of joint space narrowing for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no/normal joint space narrowing and 4 indicating complete loss of joint space, bony ankylosis, or luxation. The maximum joint space narrowing score is 168.
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Baseline | 16.47 ± 25.990 | 15.22 ± 25.012 | 15.75 ± 25.118 |
| Change at Week 24 | 0.43 ± 1.654 | 0.16 ± 1.655 | -0.07 ± 1.504 |
| Change at Week 48 | 0.68 ± 2.777 | 0.18 ± 1.471 | 0.05 ± 1.859 |
Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage.
| Percentage of Participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Week 24 | 47.5 (41.9 to 53.1) | 58.7 (53.3 to 64.1) | 65.3 (60.2 to 70.5) |
| Week 48 | 37.7 (32.3 to 43.1) | 58.7 (53.3 to 64.1) | 60.8 (55.5 to 66.1) |
mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| Percentage of Participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Percentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 48 | 11.8 (8.2 to 15.4) | 22.7 (18.1 to 27.2) | 29.8 (24.8 to 34.7) |
HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.
| Percentage of Participants | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Week 24 | 42.3 (36.9 to 47.7) | 59.8 (54.6 to 65.0) | 66.5 (61.5 to 71.5) |
| Week 48 | 34.8 (29.6 to 40.0) | 58.9 (53.7 to 64.1) | 65.9 (60.9 to 70.9) |
The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical and Mental Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Baseline: Mental Component Summary | 40.54 ± 12.282 | 39.99 ± 11.863 | 40.48 ± 12.822 |
| Change at Week 24: Mental Component Summary | 4.38 ± 10.886 | 6.11 ± 10.082 | 5.80 ± 11.224 |
| Change at Week 48: Mental Component Summary | 4.15 ± 10.326 | 6.36 ± 10.212 | 6.43 ± 11.795 |
| Baseline: Physical Component Summary | 31.86 ± 7.387 | 32.24 ± 7.401 | 31.58 ± 8.039 |
| Change at Week 24: Physical Component Summary | 5.29 ± 8.421 | 6.73 ± 8.385 | 7.71 ± 7.328 |
| Change at Week 48: Physical Component Summary | 5.28 ± 8.373 | 8.38 ± 8.347 | 9.15 ± 8.389 |
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Baseline | 27.25 ± 10.821 | 26.87 ± 10.920 | 26.57 ± 11.194 |
| Change at Week 24 | 5.14 ± 9.864 | 7.18 ± 9.755 | 7.07 ± 10.269 |
| Change at Week 48 | 5.39 ± 10.054 | 8.01 ± 10.132 | 8.41 ± 10.682 |
The modified BPI (short-form) is a short questionnaire to assess the severity of pain and the impact of pain on daily functions. The first two questions relate to average and current pain respectively and are assessed on a scale from 0 to 10, where 0 represents no pain, and 10 represents pain as bad as one can imagine. The degree to which pain has interfered with 7 different aspects is also rated on a scale from 0 to 10, where 0 represents that pain does not interfere and 10 that pain completely interferes.
| Units on scale | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Baseline: average pain | 6.39 ± 2.011 | 6.28 ± 2.077 | 6.42 ± 2.194 |
| Baseline: pain right now | 5.57 ± 2.398 | 5.75 ± 2.495 | 5.82 ± 2.533 |
| Change at Week 24: average pain | -1.82 ± 2.441 | -2.45 ± 2.299 | -2.48 ± 2.424 |
| Change at Week 24: pain right now | -1.57 ± 2.775 | -2.32 ± 2.659 | -2.24 ± 2.671 |
| Change at Week 48: average pain | -1.78 ± 2.619 | -2.92 ± 2.442 | -3.06 ± 2.422 |
| Change at Week 48: pain right now | -1.53 ± 2.795 | -2.66 ± 2.676 | -2.92 ± 2.681 |
Collected over Baseline up to 33 months.. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo × 2 IV + MTX | 5/318 (1.6%) | 73/318 (23%) | 228/318 (71.7%) |
| Ocrelizumab 200 mg × 2 IV + MTX | 2/343 (0.6%) | 61/343 (17.8%) | 272/343 (79.3%) |
| Ocrelizumab 500 mg × 2 IV + MTX | 8/345 (2.3%) | 78/345 (22.6%) | 273/345 (79.1%) |
| Event | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/318 | 4/343 | 10/345 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 4/318 | 1/343 | 2/345 |
| Urinary tract infectionInfections and infestations | 4/318 | 1/343 | 3/345 |
| SepsisInfections and infestations | 4/318 | 1/343 | 0/345 |
| Myocardial infarctionCardiac disorders | 3/318 | 1/343 | 2/345 |
| CellulitisInfections and infestations | 3/318 | 1/343 | 3/345 |
| Pyelonephritis acuteInfections and infestations | 3/318 | 0/343 | 1/345 |
| Humerus fractureInjury, poisoning and procedural complications | 0/318 | 3/343 | 1/345 |
| VomitingGastrointestinal disorders | 2/318 | 3/343 | 1/345 |
| Renal failure acuteRenal and urinary disorders | 2/318 | 3/343 | 1/345 |
| Event | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX |
|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 62/318 | 89/343 | 96/345 |
| Upper respiratory tract infectionInfections and infestations | 64/318 | 79/343 | 85/345 |
| NasopharyngitisInfections and infestations | 45/318 | 43/343 | 51/345 |
| Urinary tract infectionInfections and infestations | 40/318 | 38/343 | 48/345 |
| BronchitisInfections and infestations | 39/318 | 43/343 | 40/345 |
| HypertensionVascular disorders | 26/318 | 42/343 | 37/345 |
| SinusitisInfections and infestations | 18/318 | 33/343 | 28/345 |
| HeadacheNervous system disorders | 24/318 | 29/343 | 32/345 |
| InfluenzaInfections and infestations | 20/318 | 31/343 | 29/345 |
| Back painMusculoskeletal and connective tissue disorders | 16/318 | 19/343 | 26/345 |
| Age, Continuous(Years) | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX | Total |
|---|---|---|---|---|
| Mean | 50.5 ± 11.54 | 51.8 ± 11.97 | 50.9 ± 12.23 | 51.1 ± 11.91 |
| Sex: Female, Male(Participants) | Placebo × 2 IV + MTX | Ocrelizumab 200 mg × 2 IV + MTX | Ocrelizumab 500 mg × 2 IV + MTX | Total |
|---|---|---|---|---|
| Female | 248 | 283 | 282 | 813 |
| Male | 72 | 60 | 61 | 193 |
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Dec 2006 to primary completion in Oct 2009, 33 months.
Results were first posted in Nov 2020, 11 years 1 month after primary completion. A results delay was requested in Jun 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab